Burning Rock Biotech Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Burning Rock Biotech.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Biotechs Gewinnwachstum27.1%
Wachstumsrate der Einnahmenn/a
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

None

Zuletzt aktualisiertn/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Jun 21
Little Excitement Around Burning Rock Biotech Limited's (NASDAQ:BNR) Revenues

Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

Mar 25
Will Burning Rock Biotech (NASDAQ:BNR) Spend Its Cash Wisely?

There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Feb 01
There's No Escaping Burning Rock Biotech Limited's (NASDAQ:BNR) Muted Revenues

Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Jul 12
Burning Rock Biotech Limited (NASDAQ:BNR) Shares Could Be 24% Below Their Intrinsic Value Estimate

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

Apr 28
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Deliver On Growth Plans?

We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Dec 23
We Think Burning Rock Biotech (NASDAQ:BNR) Needs To Drive Business Growth Carefully

Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Sep 20
Is Burning Rock Biotech (NASDAQ:BNR) In A Good Position To Invest In Growth?

Burning Rock Biotech GAAP EPS of -$0.37 misses by $0.01, revenue of $19.5M misses by $2.94M

Aug 31

Burning Rock Localizes As Investors Grow Impatient

Jun 06

We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Mar 24
We're Hopeful That Burning Rock Biotech (NASDAQ:BNR) Will Use Its Cash Wisely

Following Rough Year, Is Burning Rock Set To Turn The Corner?

Nov 17

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

Aug 27
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt In A Risky Way?

A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Jul 23
A Look At The Intrinsic Value Of Burning Rock Biotech Limited (NASDAQ:BNR)

Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

May 13
Is Burning Rock Biotech (NASDAQ:BNR) Using Debt Sensibly?

Burning Rock Biotech Expands Test Portfolio In Bid For Growth

Dec 30

Burning Rock inks license pact with Oncocyte Corporation

Dec 15

Burning Rock Biotech prices upsized offering of 2.243M ADSs at $25.75/ADS

Dec 04

Burning Rock Biotech EPS misses by $0.08, beats on revenue

Nov 20

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Burning Rock Biotech jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:BNR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/2024510-567-154-144N/A
3/31/2024521-590-192-183N/A
12/31/2023537-654-265-256N/A
9/30/2023559-708-378-307N/A
6/30/2023586-764-466-396N/A
3/31/2023570-895-496-426N/A
12/31/2022563-971-527-457N/A
9/30/2022568-1,006-715-501N/A
6/30/2022540-945-608-499N/A
3/31/2022537-887-723-509N/A
12/31/2021508-797-691-478N/A
9/30/2021492-702-536-456N/A
6/30/2021490-659-545-360N/A
3/31/2021469-564-259-180N/A
12/31/2020430-472-153-74N/A
9/30/2020387-450-79-33N/A
6/30/2020367-389-53-13N/A
3/31/2020345-347-169-129N/A
12/31/2019382-334-274-228N/A
9/30/2019358-268-214-208N/A
12/31/2018209-232-173-149N/A
12/31/2017111-185N/A-134N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if BNR's forecast earnings growth is above the savings rate (2.5%).

Ertrag vs. Markt: Insufficient data to determine if BNR's earnings are forecast to grow faster than the US market

Hohe Wachstumserträge: Insufficient data to determine if BNR's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if BNR's revenue is forecast to grow faster than the US market.

Hohe Wachstumseinnahmen: Insufficient data to determine if BNR's revenue is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if BNR's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken